Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allyson Price

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of the Advanced Practitioner in Oncology|February 22, 2021
The Advanced Practitioner's Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020Allyson Price
Journal of the Advanced Practitioner in Oncology|February 4, 2021
The Role of the Advanced Practitioner in Enhancing OutcomesNancy M Nix, Allyson Price
Journal of the Advanced Practitioner in Oncology|February 4, 2021
Optimizing Use of Newly Approved Agents for Acute Myeloid LeukemiaNancy M Nix, Allyson Price
Journal of the Advanced Practitioner in Oncology|June 4, 2021
Biomarker JeopardySandra E Kurtin, Alyssa Henglefelt, Allyson Price
Leukemia Research Reports|October 25, 2021
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclaxMaria Tariq Siddiqui, Allyson Price, Alessandra Ferrajoli, et al.
Frontiers in Oncology|September 28, 2020
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical <i>FLT3</i> MutationsNaval Daver, Allyson Price, Christopher B Benton, et al.
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of the Advanced Practitioner in Oncology|February 22, 2021
The Advanced Practitioner's Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020Allyson Price
Journal of the Advanced Practitioner in Oncology|February 4, 2021
The Role of the Advanced Practitioner in Enhancing OutcomesNancy M Nix, Allyson Price
Journal of the Advanced Practitioner in Oncology|February 4, 2021
Optimizing Use of Newly Approved Agents for Acute Myeloid LeukemiaNancy M Nix, Allyson Price
Journal of the Advanced Practitioner in Oncology|June 4, 2021
Biomarker JeopardySandra E Kurtin, Alyssa Henglefelt, Allyson Price
Leukemia Research Reports|October 25, 2021
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclaxMaria Tariq Siddiqui, Allyson Price, Alessandra Ferrajoli, et al.
Frontiers in Oncology|September 28, 2020
First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical <i>FLT3</i> MutationsNaval Daver, Allyson Price, Christopher B Benton, et al.
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Pageof 1